Table 2 Efficacy of CCP, vaccinee plasma, and Vax-CCP expressed as GMT50 against Omicron sublineages
Plasma type | Number of studies | WA-1 nAb GMT50 | Omicron BA.1 nAb GMT50 (fold reduction from WA-1) | Omicron BA.2 nAb GMT50 (fold reduction from WA-1) | Omicron BA.14/5 nAb GMT50 (fold reduction from WA-1) | Total number individuals in all studies | Omicron BA.1; BA.2; BA.4/5 neutralizing percent |
|---|---|---|---|---|---|---|---|
Pre-omicron CCP | 3 | 1338 | 133 (10 FR) | 132 (10 FR) | 177 (8 FR) | 50 | 35; 37;40 |
BA.1 CCP | 3 | 71 | 366 (0.16 FR) | 180 (0.4 FR) | 82 (1 FR) | 74 | 66; 80; 76 |
BA.4/5 CCP | 1 | 904 | 557 (2 FR) | 884 (1 FR) | 1047 (1 FR) | 13 | 100; 100; 100 |
3-dose BNT162b2 plasma | 8 | 3247 | 494 (7 FR) | 511 (6 FR) | 189 (16 FR) | 159 | 97; 98; 96 |
Post-COVID-19-BA.1/full vacc plasma | 11 | 3578 | 1713 (2 FR) | 1830 (2 FR) | 454 (8 FR) | 142 | 99; 99; 99 |
